LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--RainDance Technologies, Inc., the Digital Biology™ Company, today announced new placements of its ThunderStorm™ System at the LIGAN-Personalized Medicine Equipment of Excellence at the Pasteur Institute of Lille in France and CEINGE Biotecnologie Avanzate in Naples, Italy. The ThunderStorm System is a fully automated high-throughput targeted sequencing solution that enables researchers to determine all variation contained in any region of the genome faster and easier than ever before.
“The ThunderStorm System delivers unprecedented daily sample throughput, automated walk-away operation and running economics that are significantly lower than any other commercial solution”
Leveraging RainDance’s proven single-molecule picodroplet PCR technology, the ThunderStorm System supports a wide range of sequencing applications, including candidate gene screening, deep sequencing of heterogeneous tumor samples and medical genetics testing.
At the LIGAN-Personalized Medicine Equipment of Excellence at the Pasteur Institute of Lille, researchers are focused on the development of cost-effective, high-throughput and high-quality approaches for the molecular diagnosis of genetic diseases such as monogenic forms of diabetes and obesity. Their vision is to develop solutions that are cheaper and faster than whole exome sequencing and less labor intensive than traditional Sanger sequencing while maintaining levels of sensitivity as good, or better, than this gold-standard DNA sequencing method. In addition to their own research, LIGAN will also offer services for target enrichment using the ThunderStorm System.
Professor Philippe Froguel, head of Equipex LIGAN said, "Physicians need more cost effective and quicker methods of gene screening that enable highly reliable diagnosis of genetic disorders. These conditions would benefit from the broad dissemination of genetic testing and these solutions will further support the development of genomic medicine and its promise of more personalized treatments for human diseases. The RainDance ThunderStorm System is a big step towards this direction.”
At CEINGE, researchers will use the ThunderStorm System to design panels for researching and discovering novel mutations and genes related to the onset and/or development of specific tumors or inherited human diseases. In particular, CEINGE researchers will focus on groups of multigenic diseases such as cardiomyopathies, retinal diseases and cancer hotspots.
Professor Francesco Salvatore, President and Scientific Coordinator of CEINGE said, “Today’s advanced sequencing technologies have provided an unprecedented opportunity to obtain a new understanding of disease pathogenesis that we can use to increase the sensitivity of molecular tests and better identify the mutation carriers. The ThunderStorm System provides us with an important technology to perform our sequencing experiments in larger patient populations using a high-throughput system with the capacity to enrich larger numbers of samples for use in downstream next-generation sequencing applications. The possibility to obtain high accuracy in mutation detection and a diagnostic sensitivity comparable or even higher than conventional sequencing, allows us to approach regulatory approvals very soon in different countries, such as those with CLIA environments. These activities will also be offered as service.”
“The ThunderStorm System delivers unprecedented daily sample throughput, automated walk-away operation and running economics that are significantly lower than any other commercial solution,” added Mark Dronsfield, Head of European Commercial Operations for RainDance Technologies. “The ThunderStorm System provides customers like LIGAN and CEINGE with a production-ready platform for clinical research and a validation solution for their next-generation sequencing workflows.”
RainDance is demonstrating the ThunderStorm System in exhibition booth #910 during this week’s American Society of Human Genetics (ASHG) meeting in San Francisco. Researchers from the British Columbia Cancer Agency and U.C. San Diego will also be discussing their use of RainDance’s picodroplet-based technologies during a workshop Thursday, November 7 at 12:45p.m PT. For more information about the meeting please visit www.raindancetech.com/american-society-of-human-genetics-conference-2012-ashg.
For more information about the RainDance ThunderStorm System, please visit www.RainDanceTech.com/thunderstorm.
About RainDance Technologies
RainDance Technologies, the Digital Biology™ Company, is pioneering the use of high-throughput picodroplet-based analysis in human health and life science research. The company's core RainStorm™ technology generates millions of discrete droplets that can encapsulate a single molecule, cell or reaction and be digitally analyzed and sorted one at a time. The power, precision and simplicity of picodroplets enable researchers to answer complex questions with unprecedented sensitivity and quantitation. The complete RainDance solution includes automated instrumentation, customizable bioinformatics and high-value consumables and reagents for applications including targeted next-generation DNA sequencing, methylation, digital PCR. Based in Lexington, Massachusetts, the company supports scientists around the world through its international sales and support operations and a global network of distributors and service providers. For more information, please visit www.RainDanceTech.com.
For research use only. Not for use in diagnostics procedures.
RainDance Technologies, the RainDance Technologies logo, ThunderStorm, RainStorm and Digital Biology are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.